Vantis offers with its digital long-term therapy for cardiovascular patients a solution that aims to prevent heart attacks and digitally treat cardiovascular diseases. In addition to home use, there is a digital connection to treating physicians. The first product, a digital therapy program for coronary heart disease, will be available to patients in Germany starting in summer 2021. The startup was founded in 2019. Vantis will use the seed round funding to further build its team, in addition to the product launch.
Vantis aims to reduce the risk of heart attacks
Till Jansen, founder and CEO of Vantis, explains the background:
"Acute emergency care is very good in Germany, but long-term care requires individual, continuous support for patients, which is currently not provided to a sufficient extent. Therefore, in collaboration with the Bonn Heart Center, we founded Vantis."
The startup, founded by four people—Till Jansen, Max Rödel, Kevin Wiesner, and Ulrich Klank—is based on the latest scientific findings in cardiac research. According to the founding team, using the digital application requires minimal prior digital knowledge and is intended to enable more personalized treatment than ever before. The goal of the first Vantis product is to significantly reduce the risk of heart attacks and help patients regain their vitality.
BTOV and Firstminute Capital are lead investors
Investors Btov Partners and Firstminute Capital are leading the seed round. The Think Cell founders, who also participated, were among the first angel investors and are significantly increasing the seed funding.
Jan-Hendrik Bürk, Principal at Btov Partners, says:
"Digital medical records, virtual doctor visits, prescriptions via app – the healthcare system is undergoing a transformative phase. The integration of decentralized digital solutions like Vantis enables a fundamental improvement in care."
